On the "designed to fail" ...reading the abstract it seems this had 52% vaccinated. Is this one of the issues or what are the key design parameters that setup the failure? What is known about this "COVID-OUT Trial Team"?
Dr Pierre Kory has addressed some of the common methods used to design trial failure. In the case of ivermectin, for example, and counter to practices for Covid-19 that had already been well-established, such trials used too low a dose; began treatment too late in the disease; recruited mostly young people who were unlikely to benefit much from early treatment; and/or chose trial endpoints that didn't address important outcomes.
I did notice that the trial was conducted on persons "within 3 days after a confirmed diagnosis of infection and less than 7 days after the onset of symptoms." "Less than 7" also means "up to 7." I gather that this is too late for ivermectin to be effective, yes? Wondering if readers noticed any other design flaws.
I can't remember which doc said it, but I recently heard one say that to be truly effective as an early treatment ivermectin should be started within 3 days of first symptoms. That said, ivermectin does have some degree of effectiveness through all the stages of the illness, including after the virus replication stage has ended (it has multiple modes of action). The real secret here is that a cocktail of antivirals (ivermectin and hydroxychloroquine) plus immune-supporting nutraceuticals (especially vitamin D) is the best approach to early treatment. See the FLCCC.net protocols for details.
these are based on "designed to fail" clinical trial designs.
On the "designed to fail" ...reading the abstract it seems this had 52% vaccinated. Is this one of the issues or what are the key design parameters that setup the failure? What is known about this "COVID-OUT Trial Team"?
Dr Pierre Kory has addressed some of the common methods used to design trial failure. In the case of ivermectin, for example, and counter to practices for Covid-19 that had already been well-established, such trials used too low a dose; began treatment too late in the disease; recruited mostly young people who were unlikely to benefit much from early treatment; and/or chose trial endpoints that didn't address important outcomes.
I did notice that the trial was conducted on persons "within 3 days after a confirmed diagnosis of infection and less than 7 days after the onset of symptoms." "Less than 7" also means "up to 7." I gather that this is too late for ivermectin to be effective, yes? Wondering if readers noticed any other design flaws.
I can't remember which doc said it, but I recently heard one say that to be truly effective as an early treatment ivermectin should be started within 3 days of first symptoms. That said, ivermectin does have some degree of effectiveness through all the stages of the illness, including after the virus replication stage has ended (it has multiple modes of action). The real secret here is that a cocktail of antivirals (ivermectin and hydroxychloroquine) plus immune-supporting nutraceuticals (especially vitamin D) is the best approach to early treatment. See the FLCCC.net protocols for details.